SCHEMBL11507

SCHEMBL11507

CC1CCC(NCCCN2CCCCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.48
CYP2C9 P11712 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
RAD52 P43351 2/20 0.44
FPR3 P25089 1/20 0.42
FPR2 P25090 1/20 0.42
CARM1 Q86X55 2/20 0.42
PRMT6 Q96LA8 2/20 0.42
PRMT8 Q9NR22 2/20 0.42
PRMT1 Q99873 1/20 0.42
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SIGMAR1 Q99720 3/20 0.36
TMEM97 Q5BJF2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7947655 0.85 RAD52 (0.58) HRH3CYP2C9SMN1; SMN2LMNARAD52
SCHEMBL20614282 0.85 RAD52 (0.58) HRH3CYP2C9SMN1; SMN2LMNARAD52
SCHEMBL6973435 0.83 RAD52 (0.55) HRH3CYP2C9SMN1; SMN2LMNARAD52
SCHEMBL11981495 0.83 HRH3 (0.49) HRH3CYP2C9SMN1; SMN2LMNARAD52
SCHEMBL18531871 0.82 HRH3 (0.45) HRH3CYP2C9SMN1; SMN2LMNARAD52
SCHEMBL11766 0.82 SMN1; SMN2 (0.49) HRH3CYP2C9SMN1; SMN2LMNARAD52
SCHEMBL6493217 0.80 RAD52 (0.59) HRH3CYP2C9SMN1; SMN2LMNARAD52
SCHEMBL6503351 0.80 RAD52 (0.59) HRH3CYP2C9SMN1; SMN2LMNARAD52
SCHEMBL17484488 0.79 RAD52 (0.60) HRH3CYP2C9SMN1; SMN2LMNARAD52
SCHEMBL4281737 0.79 RAD52 (0.63) HRH3CYP2C9SMN1; SMN2LMNARAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170320892-A1 Antimicrobial Compounds And Methods Of Making And Using The Same SILICON VALLEY BANK 2017-11-09 US disclosed
US-9573962-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-02-21 US disclosed
US-20150274752-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2015-10-01 US disclosed
US-9023843-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-05-05 US disclosed
WO-2011047320-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274752-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME LPO, MPO, CAT HRH3 3404/4885CYP2C9 1826/4885SMN1; SMN2 3970/4885
US-20170320892-A1 Antimicrobial Compounds And Methods Of Making And Using The Same LPO, MPO, CAT HRH3 3404/4885CYP2C9 1826/4885SMN1; SMN2 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.